secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001213900-25-109479
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD posts Q3 net income of $50K vs year-ago loss; license revenue up 43%
--------------------------------------------------------------------------------

- Net income from continuing operations was $50K ($0.00 per share) vs net loss of $567K ($0.05) in Q3 2024.
- License revenue from Mayne Agreement rose 43% to $784K from $547K year-over-year.
- Total operating expenses decreased 2.1% to $1,646K, roughly flat from prior year.
- Company evaluating strategic alternatives including M&A, sale of assets; no timetable set.
- Cash and cash equivalents stood at $7.1 million as of September 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/0001213900-25-109479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea0265416-8k_therape.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-109479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer